Woodbine, MD, Apr. 28, 2020–Rithim Biologics®, Inc. is pleased to announce the addition of Mr. Bob H. Katz to its Board of Directors effective March 1, 2020.
Bob is a proven serial life science start-up executive with a broad, multi-disciplinary background. He has excelled as an early stage specialist with unique R&D, Clinical, Regulatory and Operations successes. Mr. Katz’s background includes medical device and combination product (drug/device) development including implantables, durable medical equipment and disposables. He has been instrumental in successful PMA, IND, 510K and CE Marked product developments & regulatory approvals. His experiences span an impressive 36-year career in the fields of interventional cardiology, endovascular and vascular surgery, electrophysiology, ENT, women’s health & emergency medicine. Bob has a reputation for building effective and loyal teams and successful product introductions. He is self-driven with an entrepreneurial effort and venture fundraising experiences which have led to successful IPO and M&A outcomes. He is a named inventor on 20+ patents and has managed IP portfolios. Mr. Katz has served on the Board of Directors at ContraMed LLC and PinPointe USA, Inc., and in senior executive roles at ContraMed, LLC, PinPointe USA, Inc., Aptus Endosystems, Revivant Corporation, and Symphonix Devices, Inc. He is currently a Partner and Chief Technology Officer at Hybridge Medical, LLC.
Bob has earned his M.B.A. from the Friedt School of Business, Southeastern University; his M.S. in Biomedical Engineering from Boston University; a B.A. in Business Administration and a B.S. in Electrical Engineering both from Rutgers University.
“We are thrilled to have Bob bring his leadership and strategic and functional skills to our Board of Directors”, stated Ronald Anderson, Chairman.
For further information contact:
Ronald Anderson, randerson@rithimbiologics.com
